文献速递精神分裂症与精神病性障碍

精神分裂症的新药治疗:靶向环路功能障碍的方法综述

New Drug Treatments for Schizophrenia: A Review of Approaches to Target Circuit Dysfunction.
PubMed 文献 · Biol Psychiatry · 2024-05-28

本综述聚焦精神分裂症皮质GABA能-谷氨酸能微环路及其向皮质下多巴胺能环路的投射,梳理靶向GABA能/谷氨酸能靶点、多巴胺调节通路及PDE10A抑制剂等新药的最新临床试验证据,并讨论环路模型的局限与未来方向。

要点

  • 皮质GABA能-谷氨酸能微环路及其向皮质下多巴胺能环路的投射在阴性、认知和精神病性症状的病理病因中起关键作用。
  • 在研药物靶向GABA能或谷氨酸能靶点(甘氨酸转运体、D-氨基酸氧化酶、钠通道、钾通道)及多巴胺调节通路(毒蕈碱受体、痕量胺受体、5-HT2A受体)和PDE10A。
  • 毒蕈碱激动剂KarXT的临床数据最先进,若获批可能革新对精神分裂症病理生理和治疗的理解。

核心结论

  • 基于所综述机制的数种药物已有有希望的临床数据,其中毒蕈碱激动剂KarXT最为先进。
  • 若这些药物获批临床使用,它们有可能革新对精神分裂症病理生理和治疗的理解。

研究设计与样本

  • 综述综合了临床前、在体影像、死后、遗传学和药理学研究,并考虑新药在环路中的作用及其最新临床试验证据(适应证、疗效和副作用)。

主要发现

  • 皮质GABA能-谷氨酸能微环路及其向皮质下多巴胺能环路的投射在阴性、认知和精神病性症状的病理病因中起关键作用。
  • 抗精神病药主要作用于该环路多巴胺能组分的下游。
  • 多种在研药物靶向GABA能或谷氨酸能靶点,包括甘氨酸转运体、D-氨基酸氧化酶、钠通道或钾通道。
  • 其他在研药物可能主要作用于调节多巴胺系统的通路,如毒蕈碱受体、痕量胺受体或5-HT2A受体。
  • PDE10A抑制剂正在开发以调节多巴胺能功能障碍的下游后果。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 综述考虑了环路模型的局限性,包括是否存在神经生物学上不同的患者亚组。
  • 综述还考虑了未来方向。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Schizophrenia is a leading cause of global disease burden. Current drug treatments are associated with significant side effects and have limited efficacy for many patients, highlighting the need to develop new approaches that target other aspects of the neurobiology of schizophrenia. Preclinical, in vivo imaging, postmortem, genetic, and pharmacological studies have highlighted the key role of cortical GABAergic (gamma-aminobutyric acidergic)-glutamatergic microcircuits and their projections to subcortical dopaminergic circuits in the pathoetiology of negative, cognitive, and psychotic symptoms. Antipsychotics primarily act downstream of the dopaminergic component of this circuit. However, multiple drugs are currently in development that could target other elements of this circuit to treat schizophrenia. These include drugs for GABAergic or glutamatergic targets, including glycine transporters, D-amino acid oxidase, sodium channels, or potassium channels. Other drugs in development are likely to primarily act on pathways that regulate the dopaminergic system, such as muscarinic or trace amine receptors or 5-HT2A receptors, while PDE10A inhibitors are being developed to modulate the downstream consequences of dopaminergic dysfunction. Our review considers where new drugs may act on this circuit and their latest clinical trial evidence in terms of indication, efficacy, and side effects. Limitations of the circuit model, including whether there are neurobiologically distinct subgroups of patients, and future directions are also considered. Several drugs based on the mechanisms reviewed have promising clinical data, with the muscarinic agonist KarXT most advanced. If these drugs are approved for clinical use, they have the potential to revolutionize understanding of the pathophysiology and treatment of schizophrenia.

来源:Biol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Howes OD, Dawkins E, Lobo MC, et al. New Drug Treatments for Schizophrenia: A Review of Approaches to Target Circuit Dysfunction. Biol Psychiatry. 2024. PMID: 38815885. doi:10.1016/j.biopsych.2024.05.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。